Porphyrias: Clinical Trials

11 trials for Porphyrias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 1 recruiting, 1 withdrawn. 11 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 9, Recruiting 1, Withdrawn 1
Phase 24Completed 3, Recruiting 1

Follow Porphyrias: new trials by email Literature Review of Porphyrias trials Research Report on Porphyrias

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
ATL-001 (Ciclopirox oral solution) - Congenital Erythropoietic Porphyria (CEP)
Phase 1 / Phase 2RecruitingAtlas Molecular Pharma62026-01-292026-03-24
Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline
bitopertin - Protoporphyria
Phase 1WithdrawnWake Forest University Health Sciences2026-01-012026-01-29
Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients
Afamelanotide 16mg implant - Erythropoietic Protoporphyria
Phase 1 / Phase 2CompletedClinuvel Europe Limited282024-03-072026-07-27
A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)
Givosiran, 5-probe cocktail - Acute Intermittent Porphyria (AIP), Acute Hepatic Porphyria (AHP)
Phase 1CompletedAlnylam Pharmaceuticals102018-04-262019-03-12
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Chlorpromazine Hydrochloride - Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Phase 1CompletedCycle Pharmaceuticals Ltd.202016-11-012017-11-14
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
Givosiran - Acute Intermittent Porphyria
Phase 1 / Phase 2CompletedAlnylam Pharmaceuticals162016-10-012024-03-12
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl) - Acute Intermittent Porphyria
Phase 1CompletedAlnylam Pharmaceuticals402015-05-062018-06-14
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
rAAV2/5-PBGD vector dosage 1, rAAV2/5-PBGD vector dosage 2, rAAV2/5-PBGD vector dosage 3 - Acute Intermittent Porphyria
Phase 1CompletedDigna Biotech S.L.82012-11-012014-12-18
Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria
heme arginate, tin mesoporphyrin - Porphyria
Phase 1CompletedNational Center for Research Resources (NCRR)241998-01-012005-06-24
Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria
heme arginate, tin mesoporphyrin - Porphyria
Phase 1CompletedNational Center for Research Resources (NCRR)201998-01-012005-06-24
Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria
heme arginate, tin mesoporphyrin - Porphyria
Phase 1 / Phase 2CompletedNational Center for Research Resources (NCRR)591993-07-012005-06-24

Narrower conditions

Porphyria, Acute Intermittent (6)  ·  Metabolism, Inborn Errors (3)  ·  Rare Diseases (3)  ·  Protoporphyria, Erythropoietic (2)  ·  Coproporphyria, Hereditary (1)  ·  Porphyria, Erythropoietic (1)  ·  Protoporphyria, Erythropoietic, X-Linked Dominant (1)  ·  Vomiting (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)  ·  Genetic Diseases, Inborn (11)  ·  Metabolic Diseases (11)  ·  Nutritional and Metabolic Diseases (11)  ·  Skin Diseases (9)  ·  Skin Diseases, Genetic (9)  ·  Skin and Connective Tissue Diseases (9)  ·  Digestive System Diseases (8)  ·  Liver Diseases (8)  ·  Porphyrias, Hepatic (8)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Disease Attributes (3)  ·  Pathologic Processes (3)  ·  Signs and Symptoms (1)

Interventions

givosiran (3)  ·  heme arginate (3)  ·  tin mesoporphyrin (3)  ·  (4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone (1)  ·  Chlorpromazine (1)  ·  Ciclopirox (1)  ·  Drug Implants (1)  ·  Tablets (1)  ·  afamelanotide (1)

Sponsors

Alnylam Pharmaceuticals (3)  ·  National Center for Research Resources (NCRR) (3)  ·  Atlas Molecular Pharma (1)  ·  Clinuvel Europe Limited (1)  ·  Cycle Pharmaceuticals Ltd. (1)  ·  Digna Biotech S.L. (1)  ·  Wake Forest University Health Sciences (1)

Countries

Sweden (3)  ·  United States (3)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Netherlands (1)  ·  South Africa (1)  ·  Spain (1)

Top investigators

Karl Elmo Anderson (3)  ·  Amy Simon, MD (1)  ·  Dr. Yolandi Swart, FCPHM(SA) (1)  ·  Herbert Bonkovsky, MD (1)  ·  Jesus Prieto, MD (1)  ·  Juan Ruiz, MD (1)  ·  Nader Najafian, MD (1)  ·  Rafael Enriquez de Salamanca, MD (1)

Results publications

PMID 39363243, PMID 27212246, PMID 30726693

NIH funding

2016 (1)